AMSTERDAM, The Netherlands, Oct. 4, 2006: Amsterdam Molecular Therapeutics BV (AMT), a world leader in gene therapy, today announced the closing of its €22 million private placement financing (series A round) with four top tier venture capital firms, ABN AMRO Capital/Life Sciences (AACLS), Advent Venture Partners (Advent Ventures), Gilde Healthcare Partners and Crédit Agricole Private Equity. AACLS led the financing.
